An Update on Biochemotherapy of Advanced Gastric and Gastroesophageal Adenocarcinoma

Abstract

Gastric and gastroesophageal adenocarcinoma (GGA) are significant worldwide health problems. With most patients presenting with advanced disease, palliative chemotherapy plays a significant role in treatment. Results from recent phase III studies of cytotoxic agents in combination therapy, such as docetaxel, oxaliplatin, irinotecan, capecitabine, and S-1, have been encouraging and provide patients with additional therapeutic options. Although these forthcoming regimens have allowed for more flexible patient-tailored therapy, survival continues to be suboptimal. Although still in its infancy, targeted biotherapy, including inhibitors of the vascular endothelial and epidermal growth factor receptors, seems to be promising and its incorporation into the next generation of clinical trials will hopefully improve outcomes and help advance future treatments. This article reviews current active chemotherapeutic regimens and explores the role of novel targeted therapies in advanced GGA.

Gastric Cancer: New Drugs - New Strategies

“…The prognosis for advanced gastric cancer remains poor, the 5-year overall survival (OS) rates being approximate 15% [4,5]. Chemotherapy remains the main treatment for patients with advanced disease and targeted therapy might be an option to improve the prognosis [6]. …”

Gold Nanoparticles Prepared with Phyllanthus emblica Fruit Extract and Bifidobacterium animalis subsp. lactis Can Induce Apoptosis via Mitochondrial Impairment with Inhibition of Autophagy in the Human Gastric Carcinoma Cell Line AGS

“…Although the incidence of GC has a large geographic variation, there is a consistently high incidence of 60% in East Asia [ 2 , 3 ]. Despite the many effective treatment modalities for GC, such as surgical excision, chemotherapy, radiotherapy, targeted therapy, and a combination of these interventions, GC generally remains to have a poor prognosis and low survival rates [ 4 ]. Therefore, developing novel and highly efficient therapeutic strategies for GC is strongly recommended [ 5 ].…”

<p>Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and β-Catenin Signaling</p>

“…Perioperative treatment might be curative for patients with early-stage gastric cancer, but chemotherapy constitutes the main current therapy for gastric cancer patients. 2 Therefore, it is critical to understand the molecular and cellular mechanisms underlying gastric cancer progression and metastasis and to identify new medicines or therapies for the treatment of GC.…”